CollPlant Biotechnologies (CLGN) Competitors $2.12 -0.09 (-4.07%) As of 04/30/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLGN vs. AVR, INFU, KRMD, SKIN, MGRM, ICAD, NSPR, MBOT, FONR, and SRTSShould you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include Anteris Technologies Global (AVR), InfuSystem (INFU), KORU Medical Systems (KRMD), Beauty Health (SKIN), Monogram Orthopaedics (MGRM), iCAD (ICAD), InspireMD (NSPR), Microbot Medical (MBOT), FONAR (FONR), and Sensus Healthcare (SRTS). These companies are all part of the "medical equipment" industry. CollPlant Biotechnologies vs. Anteris Technologies Global InfuSystem KORU Medical Systems Beauty Health Monogram Orthopaedics iCAD InspireMD Microbot Medical FONAR Sensus Healthcare Anteris Technologies Global (NASDAQ:AVR) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk. Which has higher earnings & valuation, AVR or CLGN? Anteris Technologies Global has higher revenue and earnings than CollPlant Biotechnologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnteris Technologies Global$2.71M65.77N/AN/AN/ACollPlant Biotechnologies$515K47.15-$7.02M-$1.46-1.45 Do institutionals & insiders believe in AVR or CLGN? 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is AVR or CLGN more profitable? Anteris Technologies Global has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -2,680.00%. Anteris Technologies Global's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Anteris Technologies GlobalN/A N/A N/A CollPlant Biotechnologies -2,680.00%-77.05%-61.43% Does the media favor AVR or CLGN? In the previous week, Anteris Technologies Global had 3 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for Anteris Technologies Global and 2 mentions for CollPlant Biotechnologies. Anteris Technologies Global's average media sentiment score of 1.00 beat CollPlant Biotechnologies' score of 0.43 indicating that Anteris Technologies Global is being referred to more favorably in the media. Company Overall Sentiment Anteris Technologies Global Positive CollPlant Biotechnologies Neutral Does the MarketBeat Community favor AVR or CLGN? CollPlant Biotechnologies received 137 more outperform votes than Anteris Technologies Global when rated by MarketBeat users. However, 100.00% of users gave Anteris Technologies Global an outperform vote while only 60.00% of users gave CollPlant Biotechnologies an outperform vote. CompanyUnderperformOutperformAnteris Technologies GlobalOutperform Votes4100.00% Underperform VotesNo VotesCollPlant BiotechnologiesOutperform Votes14160.00% Underperform Votes9440.00% Do analysts prefer AVR or CLGN? Anteris Technologies Global presently has a consensus target price of $16.50, indicating a potential upside of 233.33%. CollPlant Biotechnologies has a consensus target price of $12.50, indicating a potential upside of 489.62%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Anteris Technologies Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anteris Technologies Global 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00CollPlant Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryAnteris Technologies Global beats CollPlant Biotechnologies on 9 of the 15 factors compared between the two stocks. Get CollPlant Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLGN vs. The Competition Export to ExcelMetricCollPlant BiotechnologiesSurgical appliances & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.29M$9.15B$5.57B$7.83BDividend YieldN/A1.64%5.11%4.22%P/E Ratio-1.3819.2722.4418.48Price / Sales47.1571.13394.09103.59Price / CashN/A19.6738.1834.62Price / Book0.864.956.774.25Net Income-$7.02M$284.66M$3.22B$248.23M7 Day Performance-4.07%0.01%1.49%0.89%1 Month Performance-17.51%1.87%4.00%3.53%1 Year Performance-63.88%-17.14%16.21%5.08% CollPlant Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLGNCollPlant Biotechnologies2.3949 of 5 stars$2.12-4.1%$12.50+489.6%-63.9%$24.29M$515,000.00-1.3870Short Interest ↑Gap UpAVRAnteris Technologies GlobalN/A$3.14+9.0%$16.50+425.5%N/A$103.57M$2.71M0.00138News CoveragePositive NewsINFUInfuSystem1.49 of 5 stars$4.91flat$13.00+164.8%-37.2%$103.19M$134.86M81.85410Positive NewsKRMDKORU Medical Systems3.2534 of 5 stars$2.24-1.3%$4.70+109.8%+26.7%$102.94M$33.65M-8.9680Upcoming EarningsNews CoverageSKINBeauty Health1.9888 of 5 stars$0.82-2.9%$2.50+204.4%-69.3%$102.86M$334.29M-1.961,030News CoverageMGRMMonogram Orthopaedics2.453 of 5 stars$2.65-1.9%$5.40+103.8%+47.7%$93.52M$364,999.00-5.6428News CoverageICADiCAD0.5851 of 5 stars$3.03-5.9%N/A+139.2%$82.92M$19.61M-23.31140Gap DownHigh Trading VolumeNSPRInspireMD2.5471 of 5 stars$2.60+0.4%$4.75+82.7%+30.9%$79.65M$7.01M-3.4750News CoverageMBOTMicrobot Medical1.8563 of 5 stars$2.23-10.4%$9.00+303.6%+165.6%$77.48MN/A-2.7920Positive NewsFONRFONAR2.3206 of 5 stars$12.16-0.7%N/A-20.3%$75.43M$101.57M10.57480Short Interest ↓SRTSSensus Healthcare2.1162 of 5 stars$4.45-3.1%$13.00+192.1%+14.4%$73.40M$41.81M11.1340Upcoming EarningsPositive News Related Companies and Tools Related Companies Anteris Technologies Global Competitors InfuSystem Competitors KORU Medical Systems Competitors Beauty Health Competitors Monogram Orthopaedics Competitors iCAD Competitors InspireMD Competitors Microbot Medical Competitors FONAR Competitors Sensus Healthcare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLGN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLGN Stock Free CLGN Stock Alerts